Lung Cancer
Volume 69, Issue 2 , Pages 232-238, August 2010

Expression of Mina53, a novel c-Myc target gene, is a favorable prognostic marker in early stage lung cancer

  • Kazutoshi Komiya

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Naoko Sueoka-Aragane

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 952 34 3531; fax: +81 952 34 2017.
  • ,
  • Akemi Sato

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Takashi Hisatomi

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Toru Sakuragi

      Affiliations

    • Department of Thoracic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Masahiro Mitsuoka

      Affiliations

    • Department of Thoracic Surgery, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Toshimi Sato

      Affiliations

    • Department of Pathology, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Shinichiro Hayashi

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan
  • ,
  • Hiroto Izumi

      Affiliations

    • Department of Molecular Biology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka 807-8555, Japan
  • ,
  • Makoto Tsuneoka

      Affiliations

    • Department of Pharmacology, Takasaki University of Health and Welfare, Takasaki 370-0033, Japan
  • ,
  • Eisaburo Sueoka

      Affiliations

    • Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan

Received 5 August 2009; received in revised form 29 September 2009; accepted 19 October 2009. published online 16 November 2009.

Abstract 

Mina53, a novel target gene product of c-Myc, is overexpressed in various malignancies. We previously demonstrated that Mina53 is overexpressed in lung cancer patients from the early clinical stages. In this paper, the association between disease prognosis and Mina53 expression in lung cancer patients is analyzed; we found that overexpression of Mina53 in lung cancer patients is associated with favorable prognosis. Statistical analysis using the Kaplan–Meier method showed that patients with negative staining for Mina53 had significantly shorter survival than patients with positive staining for Mina53, especially in stage I or with squamous cell carcinoma. Because the major cause of death in lung cancer patients after surgery is distant metastasis, the effect on cancer cell invasiveness was analyzed for the mechanisms involved in the association with favorable outcome. Overexpression of Mina53 in H226B, a lung squamous cell carcinoma cell line, inhibited cancer cell invasion. Transfection with mina53 shRNA increased the number of invading cells. These results suggest that Mina53 immunostaining is a useful prognostic marker – especially in the early stage of lung cancer – and that Mina53 negative patients should be managed particularly carefully after surgery.

Keywords: Mina53, c-myc, Lung cancer, Apoptosis, Cell invasion, Prognosis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0169-5002(09)00541-8

doi:10.1016/j.lungcan.2009.10.010

Lung Cancer
Volume 69, Issue 2 , Pages 232-238, August 2010